Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer

被引：4
|
作者：
Pujade-Lauraine, Eric [1 ]
机构：
[1] Univ Paris 05, Hop Univ Paris Ctr, Unite Canc Femme & Rech Clin, F-75004 Paris, France
来源：
JOURNAL OF GYNECOLOGIC ONCOLOGY | 2013年 / 24卷 / 03期
关键词：
TRIAL;
D O I：
10.3802/jgo.2013.24.3.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：209 / 211
页数：3
相关论文
共 50 条
  • [1] The combination of intravenous bevacizumab and metronomic oral cyclophosphamide for recurrent platinum-resistant ovarian cancer.
    Barber, Emma L.
    Neubauer, Nikki Lynn
    Zsiros, Emese
    Schink, Julian C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
    Barber, Emma L.
    Zsiros, Emese
    Lurain, John R.
    Rademaker, Alfred
    Schink, Julian C.
    Neubauer, Nikki L.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (03) : 258 - 264
  • [3] Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
    Andrikopoulou, Angeliki
    Liontos, Michalis
    Skafida, Efthymia
    Koutsoukos, Konstantinos
    Apostolidou, Kleoniki
    Kaparelou, Maria
    Rouvalis, Angeliki
    Bletsa, Garyfallia
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 571 - 576
  • [4] Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer
    Gulia, Seema
    Ghosh, Jaya
    Bajpai, Jyoti
    Rath, Sushmita
    Maheshwari, Amita
    Shylasree, T. S.
    Deodhar, Kedar
    Thakur, Meenakshi
    Gupta, Sudeep
    JCO GLOBAL ONCOLOGY, 2020, 6 : 542 - 547
  • [5] Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: A retrospective observational study
    Steck, Alexandra
    Barlin, Joyce
    Timmins, Patrick
    McElrath, Timothy
    Martin, Jovana
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S244 - S244
  • [6] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [7] Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
    Cannistra, S. A.
    Matulonis, U.
    Penson, R.
    Wenham, R.
    Armstrong, D.
    Burger, R. A.
    Mackey, H.
    Douglas, J.
    Hambleton, J.
    McGuire, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 257S - 257S
  • [8] Oral melphalan as a treatment for platinum-resistant ovarian cancer
    J Hasan
    G C Jayson
    British Journal of Cancer, 2003, 88 : 1828 - 1830
  • [9] Oral melphalan as a treatment for platinum-resistant ovarian cancer
    Hasan, J
    Jayson, GC
    BRITISH JOURNAL OF CANCER, 2003, 88 (12) : 1828 - 1830
  • [10] Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine
    Komiyama, Shinichi
    Kugimiya, Tsuyoki
    Takeya, Chiaki
    Takahashi, Rena
    Kubushiro, Kaneyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (07) : 1330 - 1334
12345